Search

Your search keyword '"Holly B. Krasa"' showing total 45 results

Search Constraints

Start Over You searched for: Author "Holly B. Krasa" Remove constraint Author: "Holly B. Krasa"
45 results on '"Holly B. Krasa"'

Search Results

1. Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis

2. Technical Review of Clinical Outcomes Assessments Across the Continuum of Alzheimer's Disease

3. Assessing What Matters to People Affected by Alzheimer’s Disease: A Quantitative Analysis

4. Assessing what matters most to patients with or at risk for Alzheimer’s and care partners: a qualitative study evaluating symptoms, impacts, and outcomes

6. Pooled Data Analysis of the Long-Term Treatment Effects of Tolvaptan in ADPKD

7. Economic Burden and Health-Related Quality of Life Associated with Current Treatments for Anaemia in Patients with CKD not on Dialysis: A Systematic Review

8. P0037POPULATION CHARACTERISTICS ACROSS AN EXPANDED POOLED DATABASE OF MULTIPLE AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE CLINICAL STUDIES

9. Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review

10. Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease

11. Prevalence of autosomal dominant polycystic kidney disease in the European Union

12. 432 Population Characteristics Across a Pooled Database of Multiple Autosomal Dominant Polycystic Kidney Disease (ADPKD) Clinical Studies

13. P4‐164: ALZHEIMER'S DISEASE PATIENT AND CAREGIVER ENGAGEMENT INITIATIVE (AD PACE): DETERMINING WHAT MATTERS MOST TO ALZHEIMER'S PATIENTS AND CAREGIVERS TO INFORM THE DEVELOPMENT OF NEW THERAPIES, PAYMENT AND COVERAGE DETERMINATIONS, AND DELIVERY OF CARE SERVICES

14. P4-673: FINDINGS FROM THE ALZHEIMER'S DISEASE PATIENT AND CAREGIVER ENGAGEMENT (AD PACE) INITIATIVE'S WHAT MATTERS MOST QUALITATIVE STUDY

15. Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database

16. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function

17. Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease

18. SP338ECONOMIC AND HUMANISTIC BURDEN OF DIALYSIS-DEPENDENT PATIENTS WITH CHRONIC KIDNEY DISEASE-RELATED ANEMIA: A SYSTEMATIC REVIEW

19. Epidemiology - renal outcomes

20. Cross-Country Comparison of Medical Resource Utilisation In Patients With Autosomal Dominant Polycystic Kidney Disease In Europe

21. Tolvaptan in Autosomal Dominant Polycystic Kidney Disease

22. Effects of tolvaptan on dyspnoea relief from the EVEREST trials

23. Continental Differences in Clinical Characteristics, Management, and Outcomes in Patients Hospitalized With Worsening Heart Failure

24. Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients With Symptomatic Heart Failure and Systolic Dysfunction

25. Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data

26. Efficacy and tolerability of a selective ?2C-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: A single-center, double-blind, placebo-controlled, randomized crossover study

27. Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC)

28. An Evaluation of Medical Resource Utilisation In Patients With Autosomal Dominant Polycystic Kidney Disease In Europe

29. Endocrine Alterations That Underlie Endotoxin-Induced Disruption of the Follicular Phase in Ewes1

30. Thyroid Hormones Act Primarily within the Brain to Promote the Seasonal Inhibition of Luteinizing Hormone Secretion in the Ewe*

31. Systemic Challenge with Endotoxin Stimulates Corticotropin-Releasing Hormone and Arginine Vasopressin Secretion into Hypophyseal Portal Blood: Coincidence with Gonadotropin-Releasing Hormone Suppression**Preliminary reports have appeared in Biol Reprod [Suppl 1] 54:93, 1996, and the 1997 Program and Abstracts of the 79th Annual Meeting of The Endocrine Society, Minneapolis, Minnesota, p 99. This work was supported by NIH Grants MH-11653 and HD-18337; the Sheep Research, Standards and Reagents, Data Analysis, and Administrative Core Facilities of the P30 Center for the Study of Reproduction (NIH Grant HD-18258); and the Office of the Vice President for Research at the University of Michigan

32. Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease

33. Economic burden and resource use associated with autosomal dominant polycystic kidney disease among a medicare population

34. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan

35. Treatment Length of Stay for Chronic Heart Failure Patients in a Hyponatremia Registry Patients in a Hyponatremia Registry

36. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment

37. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure

38. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study

40. Health-Related Quality Of Life (Hrqol) Measures In Autosomal Dominant Polycystic Kidney Disease (Adpkd)

41. PUK18 THE IMPACT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) ON PATIENTS' HEALTH RELATED QUALITY OF LIFE (HRQOL): DEVELOPMENT OF A CONCEPTUAL FRAMEWORK

42. Effects of Tolvaptan in Patients Hospitalized with Heart Failure and Renal Impairment and Hypotension in the EVEREST Trial

43. Clinical Implications of QRS Duration in Patients Hospitalized With Worsening Heart Failure and Reduced Left Ventricular Ejection Fraction

44. PCV127 EFFECT OF TOLVAPTAN ON HOSPITAL LENGTH OF STAY (LOS) WITHIN HYPONATREMIC PATIENTS HOSPITALIZED FOR HEART FAILURE

45. PCV125 EVALUATION OF THE ASSOCIATION BETWEEN SERUM SODIUM AND LENGTH OF STAY (LOS) IN PATIENTS HOSPITALIZED FOR HEART FAILURE

Catalog

Books, media, physical & digital resources